Elangovan A - Search Results

1

Pharmacotherapy for Obesity-Trends Using a Population Level National Database.

Elangovan A, Shah R, Smith ZL. Elangovan A, et al. Obes Surg. 2021 Mar;31(3):1105-1112. doi: 10.1007/s11695-020-04987-2. Epub 2020 Sep 28. Obes Surg. 2021. PMID: 32986169

2

Colorectal Cancer, Age, and Obesity-Related Comorbidities: A Large Database Study.

Elangovan A, Skeans J, Landsman M, Ali SMJ, Elangovan AG, Kaelber DC, Sandhu DS, Cooper GS. Elangovan A, et al. Among authors: elangovan ag. Dig Dis Sci. 2021 Sep;66(9):3156-3163. doi: 10.1007/s10620-020-06602-x. Epub 2020 Sep 21. Dig Dis Sci. 2021. PMID: 32954457

3

10-Year Trend of Abdominal Magnetic Resonance Imaging Compared With Abdominal Computed Tomography Scans in Inflammatory Bowel Disease.

Shah R, Elangovan A, Jordan DW, Katz J, Cooper GS. Shah R, et al. Among authors: elangovan a. Inflamm Bowel Dis. 2022 Sep 1;28(9):1357-1362. doi: 10.1093/ibd/izab284. Inflamm Bowel Dis. 2022. PMID: 34935946

4

High Burden of Obesity and Low Rates of Weight Loss Pharmacotherapy in Inflammatory Bowel Disease: 10-Year Trend.

Elangovan A, Shah R, Ali SMJ, Katz J, Cooper GS. Elangovan A, et al. Crohns Colitis 360. 2023 Mar 8;5(2):otad007. doi: 10.1093/crocol/otad007. eCollection 2023 Apr. Crohns Colitis 360. 2023. PMID: 36937138 Free PMC article.

5

Rates of repeat EGD in nondiabetic adults with glucagon-like peptide-1 receptor agonist prescription: a retrospective matched cohort study.

Elangovan A, Aggarwal P, Kaelber DC, Shah R. Elangovan A, et al. Gastrointest Endosc. 2024 Oct 9:S0016-5107(24)03549-1. doi: 10.1016/j.gie.2024.10.004. Online ahead of print. Gastrointest Endosc. 2024. PMID: 39389433

6

Disparities in Colorectal Cancer Screening Practices in a Midwest Urban Safety-Net Healthcare System.

Elangovan A, Skeans J, Lalani I, Ullah F, Roy A, Kaelber DC, Cooper GS, Sandhu DS. Elangovan A, et al. Dig Dis Sci. 2021 Aug;66(8):2585-2594. doi: 10.1007/s10620-020-06545-3. Epub 2020 Aug 20. Dig Dis Sci. 2021. PMID: 32816217

7

Underutilization of prophylactic rectal indomethacin and pancreatic duct stent for prevention of post-ERCP Pancreatitis.

Issak A, Elangovan A, Ferguson RD, Waghray N, Sandhu DS. Issak A, et al. Among authors: elangovan a. Endosc Int Open. 2021 Jul;9(7):E979-E985. doi: 10.1055/a-1460-7776. Epub 2021 Jun 17. Endosc Int Open. 2021. PMID: 34222616 Free PMC article.

8

Irritable bowel syndrome is strongly associated with the primary and idiopathic mast cell disorders.

Kurin M, Elangovan A, Alikhan MM, Al Dulaijan B, Silver E, Kaelber DC, Cooper G. Kurin M, et al. Among authors: elangovan a. Neurogastroenterol Motil. 2022 May;34(5):e14265. doi: 10.1111/nmo.14265. Epub 2021 Sep 17. Neurogastroenterol Motil. 2022. PMID: 34535952 Free PMC article.

9

When to use probiotics in luminal gastrointestinal disorders?

Elangovan A, Fischer M. Elangovan A, et al. Curr Opin Clin Nutr Metab Care. 2020 Sep;23(5):336-343. doi: 10.1097/MCO.0000000000000674. Curr Opin Clin Nutr Metab Care. 2020. PMID: 32657791 Review.

10

Microbiota modulation-based therapy for luminal GI disorders: current applications of probiotics and fecal microbiota transplantation.

Elangovan A, Allegretti JR, Fischer M. Elangovan A, et al. Expert Opin Biol Ther. 2019 Dec;19(12):1343-1355. doi: 10.1080/14712598.2019.1673725. Epub 2019 Oct 13. Expert Opin Biol Ther. 2019. PMID: 31570017 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

171 results

Search Page

Filters